Envestnet Asset Management Inc. Decreases Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Envestnet Asset Management Inc. reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,038,541 shares of the company's stock after selling 68,650 shares during the period. Envestnet Asset Management Inc. owned about 0.18% of Teva Pharmaceutical Industries worth $44,929,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $29,000. Resona Asset Management Co. Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $7,211,000. Pitcairn Co. lifted its holdings in shares of Teva Pharmaceutical Industries by 15.8% during the fourth quarter. Pitcairn Co. now owns 60,887 shares of the company's stock worth $1,342,000 after buying an additional 8,312 shares in the last quarter. Huntington National Bank raised its stake in Teva Pharmaceutical Industries by 65.0% in the 4th quarter. Huntington National Bank now owns 5,880 shares of the company's stock worth $130,000 after purchasing an additional 2,317 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $2,092,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA traded down $0.07 during mid-day trading on Tuesday, reaching $13.53. The stock had a trading volume of 5,142,458 shares, compared to its average volume of 9,901,046. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a 50 day moving average price of $15.71 and a two-hundred day moving average price of $17.79. The stock has a market capitalization of $15.34 billion, a P/E ratio of -9.33, a P/E/G ratio of 1.44 and a beta of 0.72.

Remove Ads

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on TEVA shares. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Monday. Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Finally, Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.